Division of Medical Oncology C, National Cancer Institute, Centro di Riferimento Oncologico via Franco Gallini 2, 33081 Aviano, Italy.
Crit Rev Oncol Hematol. 2012 Sep;83(3):422-31. doi: 10.1016/j.critrevonc.2011.12.004. Epub 2012 Jan 17.
Substantial progress has been made in the management of breast cancer by targeting HER2 and VEGF pathways. Although the efficacy and safety of target therapy in breast cancer have been established, no specific phase III trial has addressed these issues in the elderly population and the only data available derive from subanalyses or retrospective series. The aim of this review is to summarize the available evidence in this special population and to encourage further well designed studies in elderly breast cancer patients.
通过针对 HER2 和 VEGF 通路，乳腺癌的治疗取得了重大进展。尽管靶向治疗在乳腺癌中的疗效和安全性已得到证实，但尚无专门的 III 期临床试验针对老年人群进行研究，目前可用的数据仅来自于亚组分析或回顾性研究。本文旨在总结该特殊人群中的现有证据，并鼓励进一步在老年乳腺癌患者中开展精心设计的研究。
